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A B S T R A C T
In addition to its role in neuronal survival, the brain neurotrophic factor (BDNF) has been shown to inﬂuence
serotonin transmission and synaptic plasticity, events strongly implicated in the appearance of L-DOPA-induced
dyskinesia (LID), a motor complication occurring in parkinsonian patients after long-term treatment with the
dopamine precursor.
In order to evaluate a possible inﬂuence of BDNF in the appearance of LID, 6-OHDA-lesioned rats received a
striatal injection of diﬀerent concentrations of an adeno-associated viral (AAV) vector over-expressing either
BDNF or GFP, as control vector. Eight weeks later, animals started to receive a daily treatment with L-DOPA
(4–6 mg/kg plus benserazide 4–6 mg/kg, s.c.) or saline, and dyskinesias, as well as L-DOPA-induced rotations,
were evaluated at several time-points. Moreover, molecular changes in striatal D1 receptor-dependent cAMP/
PKA and ERK/mTORC signaling pathways, as well as, sprouting of striatal serotonin axons, were measured.
Results showed that the AAV-BDNF vector injection induced striatal over-expression of BDNF, as well as striatal
and pallidal serotonin axon hyperinnervation. Moreover, rats that over-expressed BDNF were more prone to
develop LID and L-DOPA-induced rotations, compared to the GFP-treated control group. Finally, rats that over-
expressed BDNF showed increased levels of striatal D1R-dependent signaling phospho-proteins in response to L-
DOPA administration. This study suggests that BDNF over-expression, by inducing changes in pre-synaptic
serotonin axonal trophism, is able to exacerbate maladaptive responses to L-DOPA administration.
1. Introduction
L-DOPA-induced dyskinesia (LID) is a troublesome side eﬀect that
develops in the vast majority of parkinsonian patients under chronic L-
DOPA treatment. In recent years, the serotonin system has emerged as a
key player in the appearance of LIDs and became a possible target for
pharmacological therapies (Bastide et al., 2015; Carta et al., 2007).
Indeed, an increasing body of experimental evidence suggests that
serotonin neurons can convert L-DOPA into dopamine (DA) and mediate
its release as a “false” transmitter. Due to the lack of pre-synaptic me-
chanisms able to ﬁne-tune L-DOPA-derived DA release, serotonin neu-
rons would contribute to swings in extracellular DA levels after oral
administration of L-DOPA, causing, in turn, a pulsatile stimulation of
striatal DA receptors, a key event in the appearance of abnormal
movements (Arai et al., 1995; Carta et al., 2007; Carta and Tronci,
2014; Iderberg et al., 2015; Tanaka et al., 1999). In agreement with this
scenario, toxin lesion or pharmacological blockade of serotonin neu-
ronal activity lead to almost full suppression of LID in experimental
http://dx.doi.org/10.1016/j.expneurol.2017.07.017
Received 17 May 2017; Received in revised form 21 July 2017; Accepted 26 July 2017
⁎ Corresponding author at: Department of Biomedical Sciences, Section of Physiology, University of Cagliari, Cittadella Universitaria, SS554, km 4.5, 09042 Monserrato, Italy.
1 These should all be considered senior authors.
E-mail address: manolocarta@unica.it (M. Carta).
Experimental Neurology 297 (2017) 73–81
Available online 27 July 2017
0014-4886/ © 2017 Elsevier Inc. All rights reserved.
MARK
animal models of Parkinson's disease (PD) (Beaudoin-Gobert et al.,
2015; Carta et al., 2007; Muñoz et al., 2008). In line with this evidence,
it has been recently demonstrated that LIDs are correlated with the state
of the serotonin innervation at striatal level in the rat experimental
model of PD as well as in parkinsonian patients; in fact, sprouting of
serotonin neuron terminals can further exacerbate development of LID
in parkinsonian rats (Rylander et al., 2010).
Rylander et al. have shown that LID correlates with striatal levels of
brain-derived neurotrophic factor (BDNF) in 6-OHDA-lesioned rats; this
result is in agreement with several studies, which reported that beha-
vioral sensitization to L-DOPA in 6-OHDA-lesioned rats was associated
to an upregulation of mRNA levels for BDNF and TrkB receptor in the
frontal cortex and striatum (Bordet et al., 1997; Guillin et al., 2003,
2001). Furthermore, several studies suggested that BDNF can produce
local trophic eﬀect on serotonergic neurons in the adult intact rat brain,
when directly injected as protein (Goggi et al., 2002; Mamounas et al.,
2000).
Based on the above evidence, we speculated that striatal injection of
an adeno-associated viral (AAV) vector coding for the rat BDNF gene in
6-OHDA-lesioned rats, by over-expressing the neurotrophin, would in-
duce sprouting of serotonin axons, in turn, promoting maladaptive re-
sponses to L-DOPA administration and worsening of LID. Here,
sprouting of serotonin axons was measured in terms of SERT im-
munoreactivity, which is considered a reliable index of increased den-
sity of 5-HT-positive ﬁbers or axonal varicosities (Bez et al., 2016;
Descarries et al., 1995; Rylander et al., 2010). Moreover, based on the
existence of a correlation between LID and D1 receptor-dependent
cAMP/PKA and ERK/mTORC signaling pathways (Brugnoli et al., 2016;
Decressac and Björklund, 2013; Santini et al., 2009b, 2007;
Subramaniam et al., 2011), we performed biochemical analysis in order
to clarify the molecular features underlying the behavioral eﬀects ob-
served in this study.
2. Material and methods
2.1. Production of the recombinant AAV viral vector
Transfer plasmids carrying adeno-associated viral (AAV5) inverted
terminal repeat coding for either rat BDNF or enhanced green ﬂuor-
escent protein (GFP), downstream of a cytomegalovirus enhancer hy-
brid synthetic chicken β-actin (CBA) promoter, were generated.
Transfection into HEK 293 cells was carried out using the calcium
phosphate method, and included the appropriate transfer plasmid en-
coding-enhanced BDNF or GFP and the packaging plasmids pDP5 en-
coding for the AAV5 capsid proteins. Cells were transfected with 2.5 mg
of DNA with equimolar amounts of helper and transfer DNA.
Transfected cells were incubated for 3 days before being harvested in
phosphate buﬀered saline–EDTA. The cell pellet was treated with a lysis
buﬀer (50 mM Tris, 150 mM NaCl, pH 8.4) and lysed through free-
ze–thaw cycles in a dry ice/ethanol bath. The lysate was then treated
with 21 U/ml benzonase (Sigma) for nuclear digestion. The crude ly-
sates were puriﬁed ﬁrst by ultracentrifugation (1.5 h at 350,000g at
18 °C) in a discontinuous iodixanol gradient and the virus-containing
fractions were puriﬁed with ion-exchange chromatography using fast
protein liquid chromatography. The virus suspension was then con-
centrated using a concentrator (Millipore Amicon Ultra, 100 kDa mo-
lecular weight cut-oﬀ) at 1500 g and 18 °C in two consecutive steps by
adding phosphate buﬀered saline. The physical titres of recombinant
AAV5 vectors were determined using dot blot quantiﬁcation as de-
scribed previously (Zolotukhin et al., 1999). Genome copy titres were
determined using real-time quantitative polymerase chain reaction
PCR, and the following vector concentrations were used: 1.2 × 1014
and 3.1 × 1013 genome copies/ml for BDNF and GFP, respectively. The
AAV-GFP vector was injected as a control at a dilution that matched the
number of genome copy per milliliter of the transgene of interest.
2.2. Animals
Adult male Sprague–Dawley rats (275–300 g; Harlan, Italy) were
used in the present study and housed on a 12 h light/dark cycle (light
on 7:00–19:00) with free access to food and water. All animal work was
performed in accordance with regulations set by the European Union
(EEC Council 86/609; D.P.R. 116/92).
2.3. Surgical procedures
2.3.1. Experimental parkinsonism
All 6-OHDA injections were conducted using a stereotaxic frame
with an attached Hamilton syringe and under general anesthesia, in-
duced by an i.p. injection of a 20:1 mixture of Fentanest (Pﬁzer, Italy)
and Dormitor® (Orion pharma, Italy) at a volume range of 1.4–1.6 ml.
The animals received 6-OHDA injection into the middle forebrain
bundle (16 μg free base in 4 μl in 0.02% L-ascorbic acid in 0.9% saline),
at the following coordinates relative to the bregma (Paxinos and
Watson, 2007): AP:−4.4 mm, ML: −1.2 mm; DV: −7.8 mm from the
dura, in order to achieve a complete lesion of the nigrostriatal pathway.
Injection speed was 1.0 μl/min and the syringe was kept in place for an
additional 3 min period before it was slowly retracted.
2.3.2. AAV vector injection
Surgical procedure for AAV vector injection was performed under
general anesthesia, as used for 6-OHDA. To give less damage to the
brain, a glass capillary (outer diameter 60–80 μm) was ﬁtted onto the
needle of a 5 μl Hamilton syringe. Rats received 4 μl (2 μl/site; 1 μl/
deposit) of the AAV-BDNF or AAV-GFP solution into the 6-OHDA-le-
sioned striatum at the following coordinates (ﬂat skull position) relative
to the bregma (Paxinos and Watson, 2007): AP/ML =+1/−2.8 mm,
DV =−5/−4 mm; AP/ML =+0.2/−4 mm, DV =−5.5/−4.5 mm
from the dura surface. Injection speed was 0.5 μl/min and the needle
was left in place for an additional 3 min period before it was slowly
retracted.
2.4. Experimental design
2.4.1. Eﬀect of BDNF over-expression on LID
In order to have a complete picture of the eﬀect of BDNF over-ex-
pression on development of dyskinesia, we performed diﬀerent con-
secutive experiments with escalating dilutions of the vector. Thus, we
started with an undiluted vector and then we progressively lowered the
concentration, up to 3% of the initial concentration. This was done
because it has been demonstrated that, depending on the dose, neuro-
trophic factors may have a dual action on speciﬁc brain functions (Arias
et al., 2014; Mamounas et al., 2000; Paredes et al., 2007). Thus, in a
ﬁrst set of experiments (Exp. 1, Fig. 1), three weeks after the 6-OHDA
lesion (n= 20), rats were subjected to the stepping test in order to
include in the study only rats with a severe impairment (stepping test
score between 0 and 2, data not shown). One week later, rats having a
mean not higher than two steps were divided into two well-matched
groups and subjected to the striatal injection of an undiluted AAV
vector solution for the expression of BDNF, or GFP (as a control). Eight
weeks after, rats that over-expressed BDNF or GFP were chronically
treated with L-DOPA (6 mg/kg plus benserazide 6 mg/kg, s.c., n= 8/
group), and abnormal involuntary movements (AIMs) were scored for
3 weeks. L-DOPA-induced rotational behavioral was also evaluated at
day 7 and 15 of L-DOPA treatment. At the end of the behavioral tests,
rats were killed and the brain processed for the tyrosine hydroxylase
(TH) immunohistochemical evaluation.
One more group of 6-OHDA-lesioned rats (Exp. 2, Fig. 1) were in-
jected with diﬀerent AAV vector dilutions for BDNF (10% and 20%) or
GFP, and LID was evaluated eight weeks after the virus injection. For
this experiment we also used a lower dose of L-DOPA (4 mg/kg plus
benserazide 4 mg/kg, s.c.) to better highlight the diﬀerence in AIM
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expression between the BDNF or GFP over-expressing rats (n= 6–10/
group). AIMs were evaluated for two consecutive days after L-DOPA
administration and, at day 3, rats were killed 30 min after L-DOPA in-
jection and the striatum dissected for biochemical studies, while the
midbrain processed for TH immunohistochemical evaluation. Finally, a
third group of 6-OHDA-lesioned rats (Exp. 3, Fig. 1) was injected with
two diﬀerent AAV-BDNF vector solutions (3% and 10%) or GFP (as a
control) (n= 7/group); rats were then sacriﬁced eight weeks after AAV
vector injection, without any L-DOPA challenge, for the evaluation of
the striatal serotonin terminals innervation and BDNF over-expression
by immunohistochemistry.
2.5. L-DOPA-induced dyskinesia
AIMs were evaluated according to the rat dyskinesia scale described
in detail previously (Lundblad et al., 2002; Muñoz et al., 2009; Tronci
et al., 2014). Brieﬂy, rats were placed individually in transparent plastic
cages without bedding material and scored every 20 min following drug
injection for the entire time course of dyskinesias. AIMs were classiﬁed
into three subtypes according to their topographic distribution as
forelimb, orolingual and axial behaviors. The severity of each AIM
subtype was assessed using scores from 0 to 4 (1: occasional, i.e. pre-
sent< 50% of the time; 2: frequent, i.e. present> 50% of the time; 3:
continuous, but interrupted by strong sensory stimuli; 4: continuous,
not interrupted by strong sensory stimuli).
2.6. L-DOPA-induced rotation
L-DOPA-induced rotation test was performed at day 7 and 15 during
L-DOPA treatment. Right and left full body turns were recorded over
120 min after L-DOPA injection, using automated rotometer bowls
(AccuScan Instrument Inc., Columbus, Ohio) (Tronci et al., 2012). Data
are expressed as net full body turns per min, where rotation con-
tralateral to the side of the lesion was given a positive value.
2.7. Stepping test
Stepping test was performed as previously described (Tronci et al.,
2013). The number of adjusting steps was counted while the rat was
moved sideways along a table surface (90 cm in 5 s), in the forehand
and backhand direction, for both forelimbs.
2.8. Immunohistochemistry
Perfused brains (ice-cold 4% paraformaldehyde in phosphate buf-
fered saline (PBS)) were transferred to 25% sucrose in PBS for cryo-
protection overnight, and sections of 40 μm were obtained using a
freezing microtome (Leica). Free-ﬂoating immunohistochemistry was
performed as previously described (Tronci et al., 2012). Brieﬂy, sec-
tions were incubated at room temperature with the primary antibody,
rabbit anti-TH (1:1000, Chemicon), rabbit anti-BDNF sc-546 (1:1000,
Santa Cruz), mouse anti-SERT (1:1000, Chemicon), and rabbit anti-GFP
(1:20,000, Abcam). On the second day, sections were incubated for 1 h
in a 1:200 dilution of speciﬁc biotinylated secondary antibody. After
rinsing, sections were treated with avidin-biotin complex (ABC Elite Kit,
Vector Laboratories) in KPBS for 1 h. The colour reaction was devel-
oped by incubation in 25 mg/ml 3,3′-diamminobenzidine and 0.005%
H2O2.
TH immunohistochemistry was performed to verify the dopami-
nergic lesion; all rats were found to have an almost complete loss of the
striatal and nigral TH signal (> 90%) (data not shown).
SERT-positive innervation was assessed in coronal section of
striatum (at rostral, medium and caudal level) and globus pallidus of
AAV-BDNF- and AAV-GFP-injected rats eight weeks after virus injection
and without any L-DOPA challenge. Optical density was determined
using the image analysis software ImageJ (Tronci et al., 2015).
2.9. Biochemical studies
For the determination of striatal BDNF levels, striatal proteins were
extracted from rats as previously described (Guida et al., 2015). Sam-
ples were sonicated in a lysis buﬀer (320 mM sucrose, 50 mM Tris HCl
Fig. 1. Schematic representation of the experimental plan. Exp (experiment); MFB (middle forebrain bundle); AIMs (abnormal involuntary movements); IHC (immunohistochemistry);
WB (Western blotting).
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pH 7.5, 50 mM NaCl, 1% Triton X-100, 5 mM β-glycerol phosphate,
1 mM Na3VO4, 5 mM NaF, protease inhibitor cocktail), and incubated
on ice for 30 min. Samples were spun at 12,000 g × 10 min and the
supernatant transferred to fresh microfuge tube. Aliquots of the
homogenate were used for protein determination using Bio-Rad Protein
Assay Kit (Bio-Rad, Hercules, CA). Equal amounts of total proteins
(30 μg) for each sample were loaded onto 10% polyacrylamide gels,
separated by SDS-PAGE and transferred overnight to membranes
(PVDF; Amersham Pharmacia Biotech, Uppsala, Sweden). The mem-
branes were immunoblotted overnight using selective antibodies
against BDNF (1:1000, Santa Cruz Biotechnology). BDNF optical den-
sity values were normalized using antibodies against GAPDH (1:1000,
Santa Cruz Biotechnology). For the evaluation of the striatal pThr202/
Tyr204-ERK1/2, pSer240/244-S6 and pSer845-GluR1 levels, rat striata
were processed according to a previous protocol (Subramaniam et al.,
2011). Brieﬂy, samples were sonicated in 1% SDS and boiled for
10 min. Aliquots of the total homogenate were used for protein de-
termination using Bio-Rad Protein Assay Kit (Bio-Rad, Hercules, CA).
Equal amounts of proteins (30 μg) for each sample were loaded onto
4–20% polyacrylamide gels. Proteins were separated by SDS-PAGE and
transferred to PVDF membranes (Bio-Rad Laboratories) by means of
“The Trans-Blot Turbo Transfer System” (Bio-Rad Laboratories). Mem-
branes were immunoblotted overnight using selective antibodies
against pSer240/244-S6, pThr202/Tyr204-ERK1/2 (each diluted
1:1000, Cell Signaling Technology, Beverly, MA) and pSer845-GluR1
(1:1000, PhosphoSolutions, Aurora, CO). Then, in order to remove
primary antibodies, membranes were treated with stripping solution
(StripAblot-EuroClone S.p.A-Milan, Italy), according to the manufac-
turer's protocol. Antibodies against S6, Thr202/Tyr204-ERK1/2 (both
diluted 1:1000, Cell Signaling Technology) and GluR1 (diluted 1:1000,
Chemicon, Temecula, CA, USA), that are not phosphorylation state
speciﬁc, were used, on the stripped membranes, to estimate the total
amount of proteins. Blots were then incubated in horseradish perox-
idase-conjugated secondary antibodies and target proteins visualized by
ECL detection (Pierce, Rockford, IL), followed by quantiﬁcation
through the “Quantity One” software (Bio-Rad).
Representative blots shown in the ﬁgures arise from cut out bands
and pasted for reassembling the image.
2.10. Statistical analysis
Statistical analysis was performed using GraphPad software. Group
comparisons were performed using either one-way factorial ANOVA or
two-way ANOVA, where appropriated, followed by Newman-Keuls or
Bonferroni multiple comparisons tests. For dyskinesia evaluation, the
main eﬀect was veriﬁed by nonparametric Kruskal–Wallis test. We re-
ported actual p-values from the ANOVAs. Statistical signiﬁcance was set
at p < 0.05. All values are presented in the study as mean ± SEM.
2.11. Drugs
All the drugs were diluted in 0.9% sterile saline. 6-OHDA and
benserazide were purchased from Sigma-Aldrich; L-3,4-dihydrox-
yphenylalanine methyl ester hydrochloride (L-DOPA) was purchased
from Research Organics, Cleveland, OH.
3. Results
3.1. Eﬀect of BDNF over-expression on L-DOPA-induced dyskinesia and
rotation
A ﬁrst experiment was performed using an undiluted BDNF vector
(Exp. 1). As shown in Fig. 2A, repeated administration of L-DOPA
(6 mg/kg, plus benserazide 6 mg/kg, s.c., n= 8/group) induced de-
velopment of dyskinesia in both BDNF and GFP over-expressing rats
during the course of the treatment. However, rats that over-expressed
BDNF showed a higher susceptibility to develop dyskinesia, during the
ﬁrst four L-DOPA injections, as compared to GFP control animals, while
this diﬀerence disappeared when LID reached a plateau in the two
groups. Two-way ANOVA repeated measures: Time: p < 0.05; Treat-
ment: p < 0.05; Time × Treatment: p= 0.22. Post hoc Bonferroni
multiple comparisons test: *p < 0.05 vs the same time point of GFP
100% + L-DOPA 6 group (n= 8/group).
Rotational behavior test was performed at day 7 and 15 of L-DOPA
chronic administration. BDNF over-expressing rats showed increased
rotational behavior contralateral to the lesioned striatum, in response to
L-DOPA, as compared to GFP over-expressing rats; that eﬀect was
maintained at day 15, when the diﬀerence in dyskinesia between the
two groups was no longer evident (n= 8/group; Fig. 2B–C and D–E).
For Fig. 2B–D, t-test: *p < 0.05 vs GFP 100%+ L-DOPA 6; for
Fig. 2C–E, two-way ANOVA followed by post hoc Bonferroni multiple
comparisons test: *p < 0.05 vs the same time point of GFP 100% + L-
DOPA 6 group (n= 8/group).
In order to evaluate whether lower concentrations of the BDNF
vector were able to produce similar eﬀect on dyskinesia, we also used
the AAV-BDNF vector at 10% and 20% concentrations. For these ex-
periments a lower dose of L-DOPA (4 mg/kg, plus benserazide 4 mg/kg,
s.c.) was used in the attempt to better highlight the diﬀerences in the
AIMs score between BDNF and GFP over-expressing rats (Exp. 2). As
shown in Fig. 3A, results showed that all the diﬀerent dilutions of the
BDNF vector made the rats more prone to develop dyskinesia as com-
pared to the GFP-control group (n= 7–10/group). One-way ANOVA
followed by Newman-Keuls Multiple Comparison Test: *p < 0.05 vs
GFP 5%+ L-DOPA 4 (n= 8–10/group).
To note, Western blot analysis of BDNF over-expression into the
striatum ipsilateral to the injection side showed similar protein levels
for both dilutions (Fig. 3B). One-way ANOVA followed by Newman-
Keuls Multiple Comparison Test: *p < 0.05 vs GFP 5%+ L-DOPA 4;
^p < 0.05 vs the corresponding intact side (n= 8–10/group).
3.2. Inﬂuence of BDNF over-expression on striatal D1 receptor-dependent
signaling pathways
The day after the last AIM test, rats from Fig. 3 were treated with L-
DOPA (4 mg/kg plus benserazide 4 mg/kg, s.c.) and sacriﬁced 30 min
later, in order to collect striatal tissues for Western blotting analysis.
Thus, the impact of BDNF over-expression on striatal D1 receptor-de-
pendent signaling pathways was evaluated by measuring p-GluR1 and
p-ERK, downstream targets of PKA activation, and p-S6, a downstream
eﬀector of mTORC1 activation. Rats were killed after the third L-DOPA
administration with the intention to evaluate striatal molecular changes
when the diﬀerence in AIMs score between the two experimental
groups was still evident.
Since the two diﬀerent dilutions of the AAV-BDNF vector used in
this experiment (10% and 20%) showed the same eﬀect on LID and
similar levels of BDNF protein over-expression in the striatum (Fig. 3),
these two groups of rats were considered as one. Results showed that
BDNF over-expression signiﬁcantly aﬀected PKA activity, as observed
by the higher GluR1 phosphorylation levels at Ser845 residue in the
striatum ipsilateral to the 6-OHDA lesion and to the virus injection side,
compared to GFP-treated group (Fig. 4A; n= 6–17/group). To note,
although not statistically signiﬁcant, p-GluR1 levels seemed to increase
also in the striatum contralateral to the virus injection. One-way
ANOVA followed by Newman-Keuls Multiple Comparison Test:
*p < 0.05 (n= 6–17/group).
No diﬀerences were found on p-Thr202/Tyr204-Erk levels in the
lesioned striatum injected with BDNF compared to the GFP-injected
groups (Fig. 4B; n= 6–17/group). One-way ANOVA followed by
Newman-Keuls Multiple Comparison Test: p > 0.05 (n= 6–17/
group). Conversely, a signiﬁcant increase on the p-Ser240/244-S6, a
downstream target of mTORC1 pathway was observed in the lesioned
striatum of BDNF over-expressing rats compared to GFP alone or GFP
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plus L-DOPA-treated rats (Fig. 4C; n= 6–13/group). One-way ANOVA
followed by Newman-Keuls Multiple Comparison Test: *p < 0.05 vs
the lesioned side of GFP 5%; ^p < 0.05 vs the lesioned side of GFP 5%
+ L-DOPA 4; #p < 0.05 vs the corresponding intact side (n= 6–13/
group).
3.3. Eﬀect of BDNF over-expression on serotonin axonal sprouting
A separate group of 6-OHDA-lesioned rats was used to evaluate the
eﬀect of BDNF over-expression on serotonin axonal sprouting at striatal
and pallidal level (Exp. 3). For this purpose, rats received, in the
striatum ipsilateral to the lesion, an AAV vector preparation of BDNF at
10% or GFP (5%, as a control) (n= 7/group). One more group of rats
received AAV-BDNF at 3%, in order to evaluate the eﬀect on serotonin
innervation induced by a lower concentration of the protein. BDNF 3%
was previously tested in a separate group of lesioned rats on induction
of LID, and, as observed for the higher concentrations, BDNF 3% also
increased susceptibility of rats to develop AIMs (One-way ANOVA: AIM
score at 1st day of L-DOPA: 1.07 ± 0.49 vs 7.13 ± 2.74 for GFP 5%
plus L-DOPA 4 mg and BDNF 3% plus L-DOPA 4 mg, respectively,
p < 0.05; AIM score at 2nd day of L-DOPA: 4.64 ± 1.71 vs
19.13 ± 6.97 for GFP 5% plus L-DOPA 4 mg and BDNF 3% plus L-
DOPA 4 mg, respectively, p < 0.05; n= 7/group).
Rats that over-expressed BDNF (3% and 10%) or GFP (n= 7/group)
were sacriﬁced eight weeks after virus injection without any L-DOPA
challenge. Optical density of SERT expression was measured at three
diﬀerent striatal levels and at globus pallidus level. Results showed that
6-OHDA lesion did not modify the expression of SERT compared to the
intact side, as demonstrated in the GFP-treated group (Fig. 5A–B–C).
Interestingly, both dilutions of the AAV-BDNF vector induced a sig-
niﬁcant serotonin terminal sprouting in the rostral and medial striatum
and globus pallidus. BDNF 3% also increased serotonin sprouting at
caudal striatum. High magniﬁcation images from striatum and globus
pallidus showed that the eﬀect of BDNF over-expression on SERT
Fig. 2. (A) Unilateral striatal injection of AAV-vector for the BDNF gene (undiluted solution) in 6-OHDA-lesioned rats increased the susceptibility of rats to develop AIMs during the ﬁrst
four L-DOPA (6 mg/kg plus benserazide 6 mg/kg, s.c.) administrations, compared to the GFP 100%+ L-DOPA 6 treated group. Two-way ANOVA repeated measures: Time: p < 0.05;
Treatment: p < 0.05; Time × Treatment: p= 0.22. Post hoc Bonferroni multiple comparisons test: *p < 0.05 vs the same time point of GFP 100%+ L-DOPA 6 group (n= 8/group).
The main eﬀect was also veriﬁed by nonparametric Kruskal–Wallis test.
(B–C; D–E) Rats that over-expressed BDNF also showed higher L-DOPA-mediated contralateral turning behavior at day 7 (B–C) and 15 (D–E) of L-DOPA chronic treatment, compared to the
GFP + L-DOPA 6 treated group. For Fig. 2B–D, t-test: *p < 0.05 vs GFP 100%+ L-DOPA 6; for Fig. 2C–E, two-way ANOVA followed by post hoc Bonferroni multiple comparisons test:
*p < 0.05 vs the same time point of GFP 100%+ L-DOPA 6 group (n= 8/group).
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immunoreactivity is associated with increased density of serotonin ﬁ-
bers (Fig. 5A′–B′). No diﬀerence was found in the intact side among the
experimental groups (Fig. 5A–B–C). One-way ANOVA followed by
Newman-Keuls multiple comparisons test: *p < 0.05 vs the corre-
sponding intact side; #p < 0.05 vs the lesioned side of GFP 5% group
(n= 6–7/group).
3.4. Eﬃcient viral vector-mediated over-expression of BDNF in the striatum
The AAV vector-mediated over-expression of the BDNF protein in
the striatum ipsilateral to the 6-OHDA lesion was examined by im-
munohistochemistry, eight weeks after virus delivery (Exp. 3). As
showed in Fig. 6A, the over-expression aﬀected a large portion of the
striatum both in BDNF 3% and 10% injected rats (n= 7/group).
However, high magniﬁcation images of the striatum revealed a higher
number of cells with intense BDNF staining in rats treated with BDNF
10%, compared to those injected with BDNF 3%. No cells expressing
high intense BDNF staining were found in rats injected with AAV-GFP
(Fig. 6B); by contrast, the eﬃciency of AAV-GFP infection was con-
ﬁrmed by GFP immunohistochemistry (data not shown) (n= 7).
Interestingly, the portion of the striatum that over-expressed BDNF
appeared to overlap the extension of the serotonin terminals sprouting
(Fig. 5), remarking a BDNF-mediated increase of serotonin innervation.
4. Discussion
This study demonstrates for the ﬁrst time that striatal injection of an
AAV vector coding for the rat BDNF gene induced long-term over-
expression of the neurotrophin, as well as striatal and pallidal serotonin
axon hyperinnervation in 6-OHDA-lesioned rats, as measured by SERT
immunostaining. Moreover, administration of L-DOPA to these rats re-
sulted in increased susceptibility to development of LID. The exacer-
bation of LID in the BDNF over-expressing rats was also accompanied
by up-regulation of post-synaptic markers of dyskinesia at striatal
neurons.
BDNF is already known to have trophic eﬀects on serotonin neurons
in intact rats; indeed, increased serotonin axon innervation has been
reported upon short-term exposure to the protein (Bregman et al., 1997;
Mamounas et al., 2000, 1995). Here, we demonstrate that chronic over-
expression obtained by an AAV vector produced similar eﬀect also in
DA depleted animals. Moreover, our results directly linked the aug-
mented striatal BDNF expression to the increased susceptibility to de-
velopment of AIMs. This event is likely produced via the trophic eﬀect
that BDNF exerts on striatal serotonin neuron innervation, further
supporting the key role of serotonin neurons in the appearance of LID.
Indeed, several previous studies demonstrated the ability of serotonin
neurons to contribute to unregulated DA release after L-DOPA admin-
istration (Carta et al., 2007; Carta and Tronci, 2014; Lindgren et al.,
2010). In support of a pivotal role of this source of DA release in the
appearance of LID, toxin lesion or pharmacological blockade of ser-
otonin neurons suppressed dyskinesia in parkinsonian rats and MPTP
treated monkeys (Beaudoin-Gobert et al., 2015; Carta et al., 2007;
Muñoz et al., 2008). In light with these results, serotonin terminal
sprouting would increase the buﬀering capacity for the exogenous L-
DOPA, and further dysregulate DA release; this, in turn, would lead to
the worsening of AIMs, as observed in the present study. Interestingly,
Fig. 3. (A) Unilateral striatal injection of AAV vector for the BDNF gene (10% and 20%) in 6-OHDA-lesioned rats increased the susceptibility of rats to develop AIMs at day 1 and day 2 of
L-DOPA (4 mg/kg plus benserazide 4 mg/kg, s.c.) administrations, compared to the GFP 5%+ L-DOPA 4 treated group. No diﬀerence was observed between the two diﬀerent BDNF
dilutions on AIMs expression. One-way ANOVA followed by Newman-Keuls Multiple Comparison Test: *p < 0.05 vs GFP 5%+ L-DOPA 4 (n= 8–10/group). The main eﬀect was also
veriﬁed by nonparametric Kruskal–Wallis test. (B) Western blotting quantiﬁcation of striatal BDNF expression showed the same amount of protein for both dilutions of the vector and high
levels of the protein compared to the GFP 5%+ L-DOPA 4 treated group. One-way ANOVA followed by Newman-Keuls Multiple Comparison Test: *p < 0.05 vs GFP 5%+ L-DOPA 4;
^p < 0.05 vs the corresponding intact side (n= 8–10/group).
Fig. 4. For Western blotting studies, rats that over-expressed BDNF at 10% and 20% were analyzed as one group given the similar values of AIMs and BDNF striatal expression observed.
(A) Results showed that, in BDNF plus L-DOPA (4 mg/kg plus benserazide 4 mg/kg, s.c.) treated rats, levels of p-Ser845-GluR1, an index of the cAMP/PKA signaling pathway activation,
were signiﬁcantly increased in the striatum that over-expressed BDNF, compared to the lesioned side of GFP 5% group; one-way ANOVA followed by Newman-Keuls Multiple Comparison
Test: *p < 0.05 (n= 6–17/group). (B) Analysis of p-Thr202/Tyr204-ERK striatal levels showed no diﬀerences among the experimental groups; one-way ANOVA followed by Newman-
Keuls Multiple Comparison Test: p > 0.05 (n= 6–17/group). (C) Analysis of p-Ser240/244-S6 levels, an index of ERK/mTORC1 pathway activation, showed higher levels in BDNF over-
expressing rats compared to both GFP 5% and GFP 5%+ L-DOPA 4 treated groups, in the injected striatum; one-way ANOVA followed by Newman-Keuls Multiple Comparison Test:
*p < 0.05 vs the lesioned side of GFP 5%; ^p < 0.05 vs the lesioned side of GFP 5%+ L-DOPA 4; #p < 0.05 vs the corresponding intact side (n= 6–13/group).
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PD patients with dyskinesia have been found to have a more preserved
serotonin innervation in caudate-putamen and globus pallidus, as
compared to non-dyskinetic subjects, highlighting the clinical relevance
of the animal studies (Politis et al., 2014). However, nothing is known
as to why dyskinetic patients present a relatively preserved striatal
serotonin innervation, while non-dyskinetic subjects show a reduction.
Our study may suggest a possible role of BDNF in this event.
Previous studies have shown that L-DOPA treatment can induce
BDNF expression in striatum, cortex and subthalamic nucleus of par-
kinsonian animals (Guillin et al., 2003, 2001; Zhang et al., 2006).
Moreover, Rylander et al. (2010) showed that L-DOPA administration
can induce sprouting of striatal serotonin axons in 6-OHDA-lesioned
rats. Of note, this response was also associated with increased depo-
larization-induced [3H]DA release and with a stronger release po-
tentiation by BDNF. Thus, the over-expression of BDNF that we ob-
tained by an AAV vector, is likely to exacerbate a process that would
gradually take place overtime upon daily L-DOPA administration,
leading to increased false transmitter release of DA from serotonin
neurons and post-synaptic DA receptor hypersensitization. A signiﬁcant
diﬀerence in AIM score between rats that over-expressed BDNF and
Fig. 5. (A–B) Representative photomicrographs of SERT expression in coronal sections of the striatum and globus pallidus of rats that over-expressed BDNF (3% and 10%) or GFP. (A′–B′)
60× magniﬁcation insets from striatum and globus pallidus showing SERT positive ﬁbers. Rats were killed eight weeks after virus injection without any L-DOPA challenge. (C) Optical
density analysis for SERT expression in the striatum that over-expressed BDNF showed that both dilutions of BDNF signiﬁcantly increased SERT levels in the rostral and medial striatum,
as well as in the globus pallidus, compared to the GFP control group. BDNF 3% also increased SERT expression at striatal caudal level. One-way ANOVA followed by Newman-Keuls
multiple comparisons test: *p < 0.05 vs the corresponding intact side; #p < 0.05 vs the lesioned side of GFP 5% group (n= 6–7/group).
Fig. 6. (A) Representative photomicrographs showing the
extension of the BDNF over-expression in striatal coronal
sections of 6-OHDA-lesioned rats unilaterally injected with
the AAV vector for BDNF (3% and 10%) or GFP 5%. (B) 20 X
magniﬁcation photomicrographs showing striatal neurons
that over-expressed BDNF in BDNF (3% and 10%) or GFP 5%
treated groups.
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controls was present only for the ﬁrst week of treatment, while AIM
scores were similar among groups as a plateau was reached (at least for
the undiluted vector). This event is likely to be due to the fact that, after
a certain number of L-DOPA treatments, similar eﬀect on LID was
achieved in control animals via the L-DOPA-induced endogenous BDNF.
In addition, the increased rotation observed in the BDNF over-expres-
sing rats may have partially masked the pro-dyskinetic eﬀect of L-
DOPA.
Our study also showed that the increased vulnerability of BDNF
over-expressing rats to development of LID is accompanied by higher
striatal levels of phospho-protein typically associated with dyskinesia;
in fact, BDNF over-expressing rats showed increased D1 receptor-de-
pendent cAMP/PKA and mTORC signaling cascades in response to L-
DOPA administration, compared to GFP-treated control group (Pavón
et al., 2006; Santini et al., 2007; Subramaniam et al., 2011; Westin
et al., 2007). Unlike previous studies, in the present work these cano-
nical markers of dyskinesia were not diﬀerent between the GFP L-DOPA
treated group and the GFP drug-naive animals, although there was a
clear trend. This discrepancy may conceivably be due to several factors,
including the low L-DOPA dose (4 mg/kg), the few L-DOPA treatments,
the diﬀerent animal model, or the diﬀerent approach for marker
quantiﬁcation used in this study compared to others (Lebel et al., 2010;
Rylander et al., 2009; Santini et al., 2009a; Westin et al., 2007).
It is worth to point out that BDNF is known to aﬀect other key
events involved in the appearance of dyskinesia beside induction of
serotonin axon sprouting, such as NMDA receptor traﬃcking and
channel activity, as well as striatal synaptic plasticity (Gardoni et al.,
2006; Lu, 2003; Suen et al., 1997; Woo et al., 2005; Xu et al., 2006).
Moreover, it has also been demonstrated that BDNF controls DA D3
receptor expression in rodent models of PD (Guillin et al., 2003, 2001;
Razgado-Hernandez et al., 2015). Furthermore, BDNF is able to po-
tentiate D3-mediated motor responses, and reverse striatal spine loss
(Razgado-Hernandez et al., 2015). Hence, the inﬂuence of BDNF on
dyskinesia may be due not only to its ability to aﬀect the state of the
striatal serotonin innervation, but also to its ability to aﬀect other key
post-synaptic events involved in dyskinesia. Further studies are re-
quired to investigate this possibility.
The present approach for studying the role of BDNF in dyskinesia
appears to induce supra-physiological levels of this neurotrophin; in
this sense, one may argue that such levels are never reached in phy-
siological or pathophysiological conditions. While this remains to be
further investigated, it is likely that only a low percentage of the BDNF
produced by the integrated virus is physiologically active, or, in other
words, is able to activate the BDNF receptors, promoting pre- and post-
synaptic alterations at striatal level. In line with this interpretation, no
diﬀerence in terms of dyskinesia, or SERT immunoreactivity, was seen
among the groups treated with diﬀerent vector dilutions. This is an
important observation, as BDNF has been previously seen to produce
biphasic eﬀects on serotonin axon sprouting and neurotransmitter re-
lease when acutely administered to intact rats at diﬀerent concentra-
tions (Mamounas et al., 2000; Paredes et al., 2007).
In conclusion, our data indicate that BDNF over-expression, by in-
ducing changes in pre-synaptic serotonin axonal trophism, is able to
exacerbate maladaptive responses to L-DOPA administration, sug-
gesting a possible pathophysiological role of BDNF in the appearance of
dyskinesia, at least in the rat model of PD.
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